EU API rules: India, China make progress; US seeks equivalence; criteria and template finalized
This article was originally published in SRA
Executive Summary
Drug regulators in India, China and the US are pressing on with efforts to meet the 2 July deadline of the EU Falsified Medicines Directive, under which all active pharmaceutical ingredients imported into Europe from third countries must meet EU-equivalent good manufacturing practice (GMP) standards.